◀ Back to BCL2

BCL2 — CDK13

Text-mined interactions from Literome

Pathan et al., Neoplasia (New York, N.Y.) 2001 : Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the cyclin dependent kinase inhibitor, flavopiridol, selectively blocks Bcl-2 phosphorylation induced by antimicrotubule drugs
Pathan et al., Neoplasia (New York, N.Y.) 2001 : Comparison of a variety of pharmacological inhibitors of serine/threonine-specific protein kinases demonstrated that the cyclin dependent kinase inhibitor, flavopiridol, selectively blocks Bcl-2 phosphorylation induced by antimicrotubule drugs
Veliz et al., Cancer Control 2012 (Leukemia, Lymphocytic, Chronic, B-Cell...) : These investigational agents include rituximab, alemtuzumab, ofatumumab, bendamustine, high-dose methylprednisolone, lenalidomide, lumiliximab, cyclin dependent kinase inhibitors, small modular immunopharmaceuticals, Bcl-2 inhibitors , and histone deacetylase inhibitors